These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37416284)

  • 1. Retracted: Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9870685. PubMed ID: 37416284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retracted: Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    International BR
    Biomed Res Int; 2022; 2022():9808495. PubMed ID: 36597467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.
    Wan R; Guo Y; Hao X; Wang Z; Duan J; Wang J
    Ther Adv Med Oncol; 2023; 15():17588359231179315. PubMed ID: 37389188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
    Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
    Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
    Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Hiranuma O; Yamada T; Kanda H; Nakano T; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
    JTO Clin Res Rep; 2022 Jul; 3(7):100353. PubMed ID: 35789793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
    Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
    Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Xu X; Huang Z; Zheng L; Fan Y
    Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
    Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
    Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer.
    Yao W; Zhao X; Gong Y; Zhang M; Zhang L; Wu Q; Wu L; Fan Z; Yan X; Jiao S
    ESMO Open; 2021 Apr; 6(2):100094. PubMed ID: 33780892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of durvalumab + chemotherapy
    Zou Y; Ren X; Zhang H; Wang Y; Wang H; Bai R; Zhang Z; Sun G; Xu L
    J Thorac Dis; 2023 Jun; 15(6):3339-3349. PubMed ID: 37426159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L; Chen B; Lin J; Peng J
    Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
    Yoshimura A; Yamada T; Miyagawa-Hayashino A; Sonobe Y; Imabayashi T; Yamada T; Okada S; Shimamoto T; Chihara Y; Iwasaku M; Kaneko Y; Uchino J; Inoue M; Konishi E; Takayama K
    Lung Cancer; 2019 Nov; 137():108-112. PubMed ID: 31568887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
    Ishida M; Morimoto K; Yamada T; Takeda T; Shiotsu S; Date K; Harada T; Tamiya N; Chihara Y; Takemura Y; Yamada T; Kanda H; Iwasaku M; Tokuda S; Kim YH; Takayama K
    JTO Clin Res Rep; 2023 Apr; 4(4):100493. PubMed ID: 37025120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.